De S - Search Results

1

Validation-Based Insertional Mutagenesis (VBIM), A Powerful Forward Genetic Screening Strategy.

De S, Tamagno I, Stark GR, Jackson MW. De S, et al. Curr Protoc. 2022 Mar;2(3):e394. doi: 10.1002/cpz1.394. Curr Protoc. 2022. PMID: 35316583 Free PMC article. Review.

2

Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.

De S, Cipriano R, Jackson MW, Stark GR. De S, et al. Cancer Res. 2009 Oct 15;69(20):8035-42. doi: 10.1158/0008-5472.CAN-09-1224. Epub 2009 Sep 29. Cancer Res. 2009. PMID: 19789344

3

EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.

De S, Dermawan JK, Stark GR. De S, et al. Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11721-6. doi: 10.1073/pnas.1412390111. Epub 2014 Jul 28. Proc Natl Acad Sci U S A. 2014. PMID: 25071181 Free PMC article.

4

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells.

De S, Lindner DJ, Coleman CJ, Wildey G, Dowlati A, Stark GR. De S, et al. Cancer Res. 2018 May 1;78(9):2396-2406. doi: 10.1158/0008-5472.CAN-17-1920. Epub 2018 Feb 13. Cancer Res. 2018. PMID: 29440145

5

Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.

De S, Zhou H, DeSantis D, Croniger CM, Li X, Stark GR. De S, et al. Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9680-5. doi: 10.1073/pnas.1511794112. Epub 2015 Jul 20. Proc Natl Acad Sci U S A. 2015. PMID: 26195767 Free PMC article.

6

Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.

Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C. Tan MH, et al. Among authors: de s. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9. Breast Cancer Res Treat. 2012. PMID: 21479552 Free PMC article.

7

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR. Dermawan JK, et al. Among authors: de s. Mol Cancer Ther. 2014 Sep;13(9):2203-14. doi: 10.1158/1535-7163.MCT-14-0013. Epub 2014 Jul 15. Mol Cancer Ther. 2014. PMID: 25028470 Free PMC article.

8

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.

Lindner DJ, Wildey G, Parker Y, Dowlati A, Stark GR, De S. Lindner DJ, et al. Among authors: de s. Br J Cancer. 2021 Mar;124(5):893-895. doi: 10.1038/s41416-020-01192-x. Epub 2020 Dec 1. Br J Cancer. 2021. PMID: 33257843 Free PMC article.

9

The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage.

De S, Holvey-Bates EG, Mahen K, Willard B, Stark GR. De S, et al. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2112674118. doi: 10.1073/pnas.2112674118. Proc Natl Acad Sci U S A. 2021. PMID: 34795058 Free PMC article.

10

VEGF-integrin interplay controls tumor growth and vascularization.

De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. De S, et al. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7589-94. doi: 10.1073/pnas.0502935102. Epub 2005 May 16. Proc Natl Acad Sci U S A. 2005. PMID: 15897451 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,149 results

Search Page